Analyst Sees 85% Upside for This Pharma Stock

ARVN scored a fresh "overweight" rating from Cantor Fitzgerald

Aug 6, 2019 at 2:33 PM
facebook twitter linkedin

The shares of biopharmaceutical concern Arvinas Inc (NASDAQ:ARVN) took a spill -- along with most of the stock market -- yesterday, as traders panned the company's quarterly earnings report. However, analysts at Cantor Fitzgerald aren't worried, initiating coverage of ARVN stock with an "overweight" rating and $42 price target -- nearly double yesterday's close of $22.75.

The analysts said Arvinas "is a leader in [the] underappreciated field of targeted protein degradation," and upcoming clinical data releases could be a boon for the shares. More specifically, Cantor waxed optimistic on the company's PROTAC platform, which "could emerge as a game-changing new modality," as well as its ARV-110 treatment, which could have "blockbuster potential in prostate cancer."

Since touching a record low of $10.19 on Dec. 21, ARVN stock has more than doubled, embarking on a series of higher highs and lows. The equity ultimately peaked at $28.25 on July 26, before pulling back to test its 80-day moving average. At last check, the shares were up 3.9% to trade at $23.64 -- a roughly 50% premium to ARVN's September initial public offering (IPO) price of $16.

ARVN stock chart aug 6

Should the security extend its quest for higher highs, a short squeeze could certainly add fuel to the fire. Short interest shot 21% higher during the past two reporting periods, and now accounts for more than 6% of ARVN's total available float. At the equity's average pace of trading, it would take shorts nearly a week to buy back their bearish bets.

In addition, there's room on the bullish bandwagon for more analysts. The current consensus 12-month price target on Arvinas shares is just $25.25 -- representing a slim 5.9% premium to the stock's current perch. Should the pharma stock resume its recent journey to all-time highs, a batch of price-target hikes could lure more buyers to the table.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners